Schizophrenia
Conditions
Keywords
Schizophrenia
Brief summary
The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism
Interventions
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* In- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent.
Exclusion criteria
* Known diabetes mellitus, high HbA1c, fasting plasma glucose and/or high 2h glucose-OGTT. * Previous use of atypicals (3 months) or other medications that might influence glucose metabolism * Contraindications or non-responsiveness for any of the treatments or other safety issues * Expected non-compliance to treatment and/or study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To analyze the safety/tolerability profile of quetiapine on glucose metabolism in schizophrenic patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose metabolism, blood lipid levels and weight | — |
Countries
Bulgaria, Czechia, Germany, Hungary, Norway, Romania, Slovakia, South Africa, United Kingdom
Outcome results
None listed